Commonwealth Diagnostics International Inc., (CDI), was founded on the patient-centric principle that early detection and diagnosis of functional gastrointestinal disorders results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed, state-of-the-art laboratory located in Salem, Massachusetts, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients in the diagnosis and management of some of the most common sources of digestive distress and functional gastrointestinal ailments in the world. Our product portfolio includes, but is not limited to: hydrogen and methane breath testing for Small Intestinal Bacterial Overgrowth (SIBO), Lactose Malabsorption, Fructose Malabsoprtion, Sucrose Malabsorption; Urea Breath Test for H. Pylori; IBSchek™, a proprietary ELISA based blood test for IBS-D/M; and AbStats™, an easy-to-use, non-invasive, and gastrointestinal telemetry and sensory system.
We pride ourselves on commercializing specialized diagnostic technologies and pairing them with operational solutions aimed at increasing accessibility and simplicity for patients and providers. In lieu of expensive, invasive, and inaccessible diagnostic methods, CDI provides non-invasive and cost-effective tools to generate important clinical data that assists healthcare providers in their diagnostic and treatment decisions and empowers patients by providing meaningful information about their condition. CDI’s entire portfolio of breath tests can be utilized in the patient’s home, alleviating scheduling burdens for patients, minimizing overhead costs for providers, and freeing up valuable resources for both.
Our team has demonstrated success in both creating robust support systems, customer service, and infrastructure for existing diagnostic technologies as well as developing and launching ground-breaking new diagnostic modalities in diverse markets. We focus on scalable, clinically sophisticated diagnostics that provide the data healthcare providers need to expedite proper diagnoses and targeted treatment. CDI’s current diagnostic portfolio specializes in customized Gas Chromatography, ELISA, and Liquid Scintillation Counter solutions. In addition to proudly serving patients around the globe, CDI prides itself on its partnerships with some of the most preeminent medical and health technology companies; life sciences and biotechnology organizations; academic and research institutions; key opinion leaders, and public health consortiums in the world.